Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chugai's Xeloda Obtains Additional Indications, Applies Tarceva For Pancreatic Cancer

This article was originally published in PharmAsia News

Executive Summary

The largest oncology drug maker in Japan, Roche's Japanese unit Chugai Pharmaceutical, obtained approvals for additional indications for anti-cancer drug Xeloda (capecitabine) and additional dosages for Avastin (bevacizumab). The company also submitted an application for an additional indication of pancreatic cancer for Tarceva (erlotinib), currently approved for non-small cell lung cancer in Japan

You may also be interested in...

Drug Makers Say Japan's PMDA Drug Review Performance Improving

Japan's drug review body, the Pharmaceutical and Medical Device Agency, has significantly improved performance of the drug review process, demonstrated by shortened review times and higher satisfaction ratings, said the Office of Pharmaceutical Industry Research, a policy think tank under the industry trade association Japan Pharmaceutical Manufacturers Association

Japan's MHLW Enhances Role Of Innovation In Drug Pricing, USTR Says

WASHINGTON - Japan is giving more weight to innovation when pricing new drugs

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts